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CDKN2A promoter hypermethylation has been widely related to many cancers. In astrocytomas, although
CDKN2A (p16INK4A protein) is often inactivated, there are still some controversial issues regarding the
mechanism by which this alteration occurs. Thus, we analyzed a series of astrocytomas to assess the
association between CDKN2A expression and methylation of grade IeIV tumors (WHO) and clinico-
pathological parameters. DNA extracted from formalin-ﬁxed parafﬁn-embedded material of 93 astrocytic
tumors was available for CDKN2A promoter methylation analysis and p16INK4A expression by
methylation-speciﬁc PCR and immunohistochemistry, respectively. A strong negative correlation be-
tween nuclear and cytoplasmic immunostaining and CDKN2A promoter methylation was found. Addi-
tionally, a signiﬁcant negative correlation between CDKN2A promoter methylation and age was
observed; also, female patients had statistically more CDKN2A methylated promoters (p ¼ 0.036) than
men. In conclusion, CDKN2A inactivation by promoter methylation is a frequent event in astrocytomas
and it is related to the age and sex of patients.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The astrocytomas are the most common primary brain tumors,
being classiﬁed according to their histological degree of malignancy
by the World Health Organization (WHO) in grades IeIV. These
categories result from the recognition of anaplasia ﬁndings, such as
nuclear atypia, cell pleomorphism, mitotic activity, endothelial
hyperplasia and necrosis.1,2
Individually or in combination with genetic mechanisms,
epigenetic alterations, such as aberrant hypermethylation of pro-
moter regions, affect the expression of tumor suppressor genes andeará, Faculdade de Medicina
lexandre Baraúna, 949 Por-
þ55 85 9924 0929; fax: þ55
.S. Alves).
ciates Ltd. Published by Elsevier LtDNA repair genes, leading to their silencing.3 Blocked expression of
tumor suppressor genes or impairment of their products may result
in loss of proliferative control, leading to the neoplastic process in
the development of many human tumors.4
In astrocytomas, besides p53 and MGMT [a speciﬁc predictive
biomarker of tumor responsiveness to chemotherapy with alky-
lating agents5], the p16INK4A (cyclin-dependent kinase inhibitor 2A-
CDKN2A) protein, encoded by the CDKN2A gene, is often inacti-
vated.6,7 This protein is a cell cycle regulator involved in the inhi-
bition of the formation of cyclin D1/cyclin-dependent kinase 4 or 6
complexes during the G1 phase (Gap1) of the cell cycle.6 Although,
in most human tumors, gene promoter hypermethylation is a
commonmechanism of CDKN2A inactivation, in astrocytomas there
are still some controversial issues.8e13 Also, few studies have
evaluated this process considering the expression and the
methylation status of this gene taking in account clinicopatholog-
ical aspects, such as histological grade and age.8,9,14 Additionally,d. All rights reserved.
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localization of the p16INK4A protein expression.15e17
Therefore, in this study, we performed an analysis of CDKN2A
expression andmethylation status in a series of astrocytic tumors of
different grades (WHO) from the state of Ceará, Brazil. We also
investigated the relationship between these aspects and clinico-
pathological parameters.
2. Material and methods
2.1. Ethical issue and casuistry
The present study was approved by the Ethics Committee of the Hospital
Complex of the Federal University of Ceará under protocol 32/2004, respecting the
Resolution 196/96 of the National Council of Health e Ministry of Health/Brazil.
Ninety-three formalin-ﬁxed parafﬁn-embedded astrocytic tumors from the archives
of the BIOPSE (Biomédica, Pesquisas e Serviços Ltda. e Fortaleza, CE e Brazil), a
private pathology laboratory which is reference in this ﬁeld in our region, selected
from the routine histopathological examinations performed between 2003 and
2011, were examined. The samples were sliced at 5 mm thickness and processed for
histopathological evaluation (hematoxylineeosin stain), DNA extraction (for MS-
PCR) and immunohistochemical analysis.
2.2. DNA extraction from parafﬁn-embedded specimens
All specimens included in this study were taken from parafﬁn-embedded tis-
sues. Ten sections from each sample were obtained from the blocks with adequate
precaution to prevent contamination between cases, including replacement of
blades between each block. Microtome holders were cleaned using xylene between
cases to prevent contamination of tissue from one block to the next. Deparafﬁni-
zation was performed through xylol baths at 65 C, rehydrated with solutions of
decreasing concentrations of ethanol and deionized water. DNAwas extracted using
a Wizard Genomic DNA Puriﬁcation Kit (Promega, Madison, USA). DNA quality was
analyzed by 1% agarose gel electrophoresis, and the amount was determined using
the NanoDropTM 3300 ﬂuorospectrometer (Wilmington, DE, USA).
2.3. Sodium bisulﬁte treatment and methylation-speciﬁc PCR (MS-PCR)
DNA extracted from parafﬁn-embedded tumor tissue was modiﬁed by sodium
bisulﬁte to determine the methylation status of the CDKN2A gene by MS-PCR, as
previously described by Ferrasi et al.18 The primers targeted to the promoter CDKN2A
region were 50-TTATTAGAGGGTGGGGCGGATCGC-30 (sense) and 50-GACCCCG
AACCGCGACCGTAA-30 (antisense) for the methylated CDKN2A (150 bp), and 50-TT
ATTAGAGGGTGGGGTGGATTGT-30 (sense) and 50-CAACCCCAAACCACAACCATAA-30
(antisense) for the unmethylated CDKN2A (151 bp). PCR was performed in 25 mL
reaction volume, containing 1 Platinum Taq buffer, 3.0 mMMgCl2, 0.4 mM of each
dNTP, 0.64 mM of each primer set, 1 U Platinum Taq DNA Polymerase (Invitrogen,
Foster, CA, USA), and 50 ng of treated DNA.
DNAmethylated in vitro by Sss-I methylase (New England Biolabs, Beverly, MA,
USA) was used as a positive control. Water and DNA from peripheral lymphocytes of
healthy donors were used as negative controls. The PCR products were resolved in a
6% non-denaturing polyacrylamide gel and subsequently submitted to silver
staining.Fig. 1. Immunohistochemical staining for p16INK4A protein in formalin-ﬁxed parafﬁn-embe
nuclear and cytoplasmic staining; [B] Glioblastoma (WHO Grade IV): diffuse staining.2.4. Immunohistochemistry
Immunostaining was performed according to a previously described protocol.19
For antigen retrieval, deparafﬁnized sections were pretreated by heating in a mi-
crowave oven in 10mM citrate buffer, pH 6.0, for 20min. After cooling, sectionswere
immersed in PBS containing 3% hydrogen peroxide for 10 min to block endogenous
peroxidase activity. Sections were then incubated in a moist chamber overnight at
4 C with p16 primary antibody (clone 6H12; dilution 1:40; Novocastra, United
Kingdom). After rinsing with PBS, the slides were incubated with secondary anti-
body followed by streptavidinebiotin-peroxidase complex (LSAB þ system;
DakoCytomation, USA), both for 30 min at room temperature with a PBS wash
between each step. The reaction was revealed with diaminobenzidine-H2O2
(DAB þ system; DakoCytomation, USA), counterstained with Harry’s hematoxylin
and mounted. A conﬁrmed case of nuclear p16-positive human breast carcinoma
was used as a positive control. Controls of primary antibody speciﬁcity included
omission or substitution of primary antiserum by normal bovine serum.
2.5. Immunostaining analyses
The immunohistochemical evaluation for p16 was performed independently by
two experienced technicians, using direct light microscopy. Any conﬂicting results
were jointly considered for a consensual determination. Protein expression was
quantiﬁed by manual counting of at least 1000 tumor cells in 10 different ﬁelds at a
magniﬁcation of400. The labeling index (LI) expresses the percentage of nuclear or
cytoplasmic positive cells in each tumor sample and H-score takes into account the
intensity of the cytoplasmic p16 stain expressed in values ranging from 0 to 3 (0¼ no
stain, 1 ¼ weak, 2 ¼moderate and 3 ¼ strong), following the methods described by
McCarty et al.20 Only cases with LI equal to or greater than 5% were considered
positive.
2.6. Statistical analyses
The statistical analyses were carried out using the SPSS version 15.0 program
(Chicago, IL, USA). Statistically signiﬁcant differences were evaluated by the chi-
square test (c2) or Fisher’s exact test. Correlations between immunostaining and
CDKN2A promoter region methylation status were analyzed by Spearman’s rank
correlation coefﬁcient. The results were considered statistically signiﬁcant when the
p-values were less than 0.05.
3. Results
3.1. Patient characteristics
A total of 93 samples of formalin-ﬁxed parafﬁn-embedded
astrocytic tumors of different grades (WHO classiﬁcation), 17
(18.3%) grade I, 19 (20.4%) grade II, 14 (15.1%) grade III, and 43
(46.2%) glioblastomas were included in this study. The median age
of the patients was 42 years (range, 2e81 years). A signiﬁcant
positive correlation (p ¼ 0.000; R ¼ 0.677) was observed between
age and grade of malignancy of tumors. Among the cases, 50 were
men and 43 women.dded astrocytic tumors (400). [A] Pilocítico Astrocytoma (WHO Grade I): moderate
Fig. 2. Polyacrylamide gel 6% to detect speciﬁc fragments of 150 pb and 151 pb for
CDKN2A methylated and non-methylated, respectively. M e Methylated, U e Non-
methylated.
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regions and expression of CDKN2A
Nuclear and/or cytoplasmic p16INK4A positivity was found only
in tumor cells. No staining was seen in non-tumor specimens. Ex-
amples of immunostaining for p16INK4A and promoter methylation
CDKN2A are illustrated in Figs.1A,B and 2. The presence of promoter
methylation in CDKN2Awas observed in 65.6% (61/93) of the cases
and expression of nuclear and cytoplasmic p16INK4A protein were
observed in 26.5% (25/93) and 51.6% (48/93) of the cases, respec-
tively. The concurrence (þ/þ) and agreement (þ/þ or /) of nu-
clear and cytoplasmic expression of p16INK4A occurred in 20.4% (19/
93) and 62.4% (58/93) of the analyzed cases, respectively. A high
signiﬁcant negative correlation was found between p16INK4A nu-
clear or cytoplasmic immunopositivity and CDKN2A promoter re-
gionmethylation (p< 0.001; R¼0.378 and p< 0.001; R¼0.384,
respectively).
3.3. Relationship among promoter methylation and expression of
the CDKN2A, age and sex of the patients
Fig. 3[A]e[B] shows the frequencies of CDKN2A promoter
methylation and p16INK4A expression stratiﬁed according to age and
sex of the studied patients. From these ﬁgures, it is possible to
observe that besides a relevant frequency of CDKN2A promoter
methylation found in all age intervals, the younger patients (<30
years old) had the highest frequencies of methylated CDKN2Awhen
compared to patients aged  30, with statistical signiﬁcant
(p ¼ 0.002). Indeed, correlation analysis showed a signiﬁcant
negative correlation between CDKN2A promoter methylation and
age (p ¼ 0.047, R ¼ 0.206). Additionally, female patients had
statically more CDKN2A methylated promoters (33/43; 76.7%;
p ¼ 0.036) than men (Fig. 3[A]). No signiﬁcant correlation between
patient age and sex and p16INK4A expression (nuclear or cyto-
plasmic) was found (Fig. 3[B]).
3.4. Relationship between promoter methylation and expression of
CDKN2A and histological grade of tumors
The distribution of the p16INK4A expression and methylation
status according to tumor grade is showed in Table 1 and Fig. 4. TheFig. 3. Frequencies of CDKN2A methylation status [A] and expression [B] acchigh frequency of 16INK4A nuclear negative cases was specially
observed among the diffuse grade tumors. Additionally, grade I
astrocytic tumors demonstrated median values of nuclear LI
signiﬁcantly higher (Median LI: 3.0) than diffuse tumors (grades II
to IV) (Median LI: 0.0) (p < 0.01) (Fig. 4).
Conversely, when analyzing the expression of cytoplasmic
p16INK4A, it was observed (Table 1 and Fig. 4) that the frequency of
positivity, the median value of cytoplasmic LI and the H score was
positively correlated to histological tumor grade (p ¼ 0.001,
R ¼ 0.337; p < 0.001, R ¼ 0.386; p < 0.001, R ¼ 0.375, respectively).
Also, grade IV tumors showed higher LI and HS median values than
the other grades, with statistical signiﬁcance (p < 0.001).
No correlation between tumor grade and CDKN2A promoter
methylation was observed (Table 1).4. Discussion
In many human tumors, the inactivation of the tumor sup-
pressor p16INK4A protein by promoter hypermethylation of its
codifying gene is a frequent event, and it has been associated with
the carcinogenesis process.21,22 Up to date, there are only few
studies on astrocytomas addressing mechanisms that may lead to
p16 inactivation, presenting controversial results.8,9,11,12,23e25
Additionally, these studies did not evaluate the data taking the
immunoexpression and the methylation status of the CDKN2A gene
combined according to histological and clinical aspects.
Similar to other studies,11,26 our study found that only 26.5% of
the tumors showed nuclear p16INK4A immunoexpression. Addi-
tionally, the positivity of p16INK4A was higher in pylocytic tumors
than in the diffuse ones, which could represent a way to hinder the
tumorigenic process, since those tumors present benign features,
with minor molecular modiﬁcations.1,27 On the other hand, 51.6% of
the tumors were p16INK4A cytoplasmic immunopositive. The
concurrence or agreement maintained between p16INK4A nuclear
and cytoplasmic staining indicates that cytoplasmic staining was
speciﬁc and not artifactual. According to Liang et al.,28 cytoplasmic
staining indicates the accumulation of this protein in the cyto-
plasm, caused by its phosphorylation mediated by protein kinase B,
oncogenetically activated, which blocks the recognition of its sites
by nuclear importation factors. In this study, p16INK4A cytoplasmic
staining was positively correlated to tumor grade, suggesting that
the greater genomic instability of the higher grade tumors27 could
lead to the expression of p16INK4A; however, due to the acquisition
of new molecular modiﬁcations, p16INK4A nuclear importation
could be blocked, explaining our ﬁndings.
Homozygous deletion has been described as the inactivating
mechanism of the CDKN2A gene, in gliomas. However, some studies
have found CDKN2A promoter methylation in astrocytic tu-
mors.8,12,13,25,29 Among the studies related to the CDKN2A promoter
methylation in astrocytomas, some publications found a very lowording to age and sex distribution of the 93 patients studied. *p < 0.05.
Table 1
Positive index of p16INK4A (nuclear and cytoplasmic) immunostaining and CDKN2A promoter methylation according to histological classiﬁcation of the cases studied (n ¼ 93).
WHO histological classiﬁcation
NT (%) I (%) II (%) III (%) IV (%) Diffuse (%) Total
p16INK4A (Nuclear) (D) 0(0) 7(41) 2(10) 3(21) 13(30) 18(24) 25
(L) 5(100) 10(59) 17(90) 11(79) 30(70) 58(76) 68
p16INK4A (Cytoplasmic) (D) 0(0) 7(41) 5(26) 6(43) 30(70) 41(54) 48
(L) 5(100) 10(59) 14(74) 8(57) 13(30) 35(46) 45
p16INK4A (Nuclear/cytoplasmic) (D/D) 0(0) 3(18) 0(0) 3(21) 13(30) 16(21) 19
CDKN2A M 2(40) 12(71) 15(79) 10(71) 24(56) 49(65) 61
U 3(60) 5(29) 4(21) 4(29) 19(44) 27(35) 32
Total 5(100) 17(100) 19(100) 14(100) 43(100) 76(100) 93
NT e Non-tumor; M e Methylated; U e Non-methylated.
Fig. 4. Median scores attributed to tumor suppressor protein nuclear p16INK4A (LI) and cytoplasmic p16INK4A (LI and H) immunostaining according to histological classiﬁcation of the
cases studied (n ¼ 93). LI (Labelling Index); H (H-Score); NT (Non-tumor); (**) p < 0.01; (***) p < 0.001.
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frequency of methylation in CDKN2A promoter was observed in
about 70% of tumors of all grades, except for grade IV tumors, which
dropped to 60%, in agreement with other studies.8,11 Methylation in
the CDKN2A promoter appears to be the mechanism blocking
p16INK4A expression in astrocytomas, since a direct strong negative
correlation between immunohistochemical expression and
methylation was observed. These data conﬁrm that methylation in
the promoter regions appears to be the main mechanism of gene
silencing, as indicated in studies by Park et al.11 and Alves et al.22
and that mutation does not appear to be a common phenomenon
in astrocytomas.12
To investigate the factors that may inﬂuence promoter
methylation in astrocytomas, we next correlated clinical patient
characteristics with CDKN2A expression and CDKN2A promoter
methylation status. In this study, there was a striking correlation
between age at diagnosis and gender and CDKN2A promoter
methylation, with a predominance of methylated CDKN2A in young
female patients. Few reported studies focusing on methylation in
astrocytic tumors have taken into account sex and age. Yu et al.,9 in
a study of methylation in astrocytomas, did not ﬁnd this relation-
ship for CDKN2A, and besides, hypermethylation of the AR genewas
found to occur frequently in females. Li et al.,30 studying genes
other than CDKN2A, found an association between N33 and ER
methylation in older glioblastoma patients but not in younger pa-
tients, although both of these genes are more often methylated in
normal elder individuals than in the younger ones. As genepromoter methylation pattern changes with age and hormonal
status,31e36 it seems reasonable to take into account both param-
eters in the analysis. Alternatively, triggering factors (genetic pre-
disposition, carcinogen exposure) may be signiﬁcantly different
between the young and older group of patients with astrocytomas,
and these factors may then inﬂuenciate the incidence of CDKN2A
methylation.
In summary, CDKN2A inactivation by promoter methylation is a
frequent event in astrocytomas and is related to age and sex of
patients. Our data suggest important interplay between gene
methylation and aging and sex in tumorigenesis, but future studies
should address the functional signiﬁcance of the methylation
events observed in astrocytomas.
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